1. Home
  2. ORIS vs GLTO Comparison

ORIS vs GLTO Comparison

Compare ORIS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ORIS

Oriental Rise Holdings Limited Ordinary Shares

HOLD

Current Price

$1.42

Market Cap

49.0M

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$30.50

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORIS
GLTO
Founded
2014
2011
Country
China
Denmark
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
54.5M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
ORIS
GLTO
Price
$1.42
$30.50
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$41.00
AVG Volume (30 Days)
479.4K
214.0K
Earning Date
04-30-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$12,317,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$171.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$2.01
52 Week High
$45.60
$38.33

Technical Indicators

Market Signals
Indicator
ORIS
GLTO
Relative Strength Index (RSI) 53.13 57.99
Support Level $1.11 $19.85
Resistance Level $1.30 $30.03
Average True Range (ATR) 0.12 2.93
MACD -0.05 0.26
Stochastic Oscillator 34.62 90.32

Price Performance

Historical Comparison
ORIS
GLTO

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: